ICON PLC

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Retrieved on: 
Tuesday, April 2, 2024
Independent, Business school, Bachelor of Science, Engineering, Bristol Myers Squibb, Thayer School of Engineering, Immunology, Therapy, Corporate development, Corporation, True north, ICON PLC, Business, Dartmouth College, Biogen, ATP, Genzyme, Cardiology, Biomedical engineering, Novo Nordisk, Drug discovery, Tuck School of Business, Acquisition, University, MBBS, AbbVie, Bioverativ, ICON, CBO, Columbia University, Biology, MBA, Hidradenitis suppurativa, TRML, Partner, Military, Management

The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.

Key Points: 
  • The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.
  • The recent board appointments include Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors.
  • He has spent over a decade specializing in founding, building and investing in biotech companies.
  • Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

ICON Announces CFO Transition

Retrieved on: 
Wednesday, April 3, 2024
Professional Services, Medical Devices, Health, Finance, Pharmaceutical, Biotechnology, ICON PLC, Pleasure, ICLR, PRA Health Sciences, Growth, CFO, Management

Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer.

Key Points: 
  • Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer.
  • ICON has commenced a search to identify the next CFO.
  • “On behalf of the ICON Board and Leadership Team, I want to thank Brendan for his strong contributions to ICON over his 18 years, including 12 years as CFO,” said Steve Cutler, ICON’s CEO.
  • We have commenced a search to identify our next CFO and will update on that process at the appropriate time.

ICON plc Schedules First Quarter 2024 Earnings Conference Call

Retrieved on: 
Monday, March 25, 2024
Professional Services, Health, Other Professional Services, Finance, Clinical Trials, Pharmaceutical, Biotechnology, ICLR, ICON PLC

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, April 24, 2024.

Key Points: 
  • ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, April 24, 2024.
  • The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, April 25, 2024 at 8:00am ET.
  • Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “ Events ”.
  • A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.

Central Lab Market Projected to Reach $5.78 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 29, 2024
Genomics, Medicine, Growth, Health, Intelligence, ICON, Biomarker, Research, Bioanalysis, Artificial intelligence, ICON PLC, Anatomy, Drug, Clinical trial, Heart, Safety, Bangladesh Technical Education Board, Table, Government, Pharmaceutical industry

Central labs are overcoming these issues through technological innovation, strategic partnerships, and broadening their global reach to provide local services that meet international standards.

Key Points: 
  • Central labs are overcoming these issues through technological innovation, strategic partnerships, and broadening their global reach to provide local services that meet international standards.
  • The central lab market is witnessing substantial growth in the Americas, powered by increased clinical trial activities and a strong research infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Central Lab Market.
  • "Dive into the Central Lab Market Landscape: Explore 198 Pages of Insights, 388 Tables, and 24 Figures"

Central Lab Market Projected to Reach $5.78 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 29, 2024
Genomics, Medicine, Growth, Health, Intelligence, ICON, Biomarker, Research, Bioanalysis, Artificial intelligence, ICON PLC, Anatomy, Drug, Clinical trial, Heart, Safety, Bangladesh Technical Education Board, Table, Government, Pharmaceutical industry

Central labs are overcoming these issues through technological innovation, strategic partnerships, and broadening their global reach to provide local services that meet international standards.

Key Points: 
  • Central labs are overcoming these issues through technological innovation, strategic partnerships, and broadening their global reach to provide local services that meet international standards.
  • The central lab market is witnessing substantial growth in the Americas, powered by increased clinical trial activities and a strong research infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Central Lab Market.
  • "Dive into the Central Lab Market Landscape: Explore 198 Pages of Insights, 388 Tables, and 24 Figures"

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Monday, March 25, 2024
Catalent, Medical device, Temperature, Growth, Prevalence, Face, Molecule, Thermo Fisher Scientific, Medication, CTSL, Pharmacy, Partnership, Intelligence, Imp, Conditional sentence, ICON, Global health, Research, Good manufacturing practice, IMP, Transport, ICON PLC, Placebo, Infosys, GMP, Excipient, Investment, Clinical trial, GDP, Drug development, API, Clinical data management, Table, Ageing, Parexel

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points: 
  • "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
    Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
  • South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
  • "Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Monday, March 25, 2024
Catalent, Medical device, Temperature, Growth, Prevalence, Face, Molecule, Thermo Fisher Scientific, Medication, CTSL, Pharmacy, Partnership, Intelligence, Imp, Conditional sentence, ICON, Global health, Research, Good manufacturing practice, IMP, Transport, ICON PLC, Placebo, Infosys, GMP, Excipient, Investment, Clinical trial, GDP, Drug development, API, Clinical data management, Table, Ageing, Parexel

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points: 
  • "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
    Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
  • South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
  • "Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Bioforum Expands Leadership Team with Appointment of Michael Goedde as President

Retrieved on: 
Tuesday, March 19, 2024
Automation, ChromeOS, Sanofi, Development, MedImmune, NESS, ICON PLC, Database, CLZ, Goedde, Trustee, CNS, ICON, Biostatistics, Research, Hoechst AG, Society, SDTM, BioGRID, Human Genome Sciences, Parexel, Nursing

NESS ZIONA, Israel, March 19, 2024 /PRNewswire/ -- Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the appointment of Michael Goedde as its President. A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy. 

Key Points: 
  • A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy.
  • "As we expand our presence in North America and around the world, I'm delighted to welcome Michael to the Bioforum family and confident that his leadership will be invaluable in driving our long-term growth and success."
  • Prior to ICON, Goedde spent four years at Parexel in roles of increasing responsibility, most recently as Vice President of Global Data Operations.
  • He holds a bachelor's degree in computer science from Computer Lern Zentrum (CLZ) Hoechst AG in Frankfurt, Germany.

ICON plc to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, February 26, 2024
Research, Medical Devices, Finance, Clinical Trials, Health Technology, Professional Services, Biotechnology, Pharmaceutical, Health, Science, CFO, ICLR, Barclays, ICON PLC, Conference

ICON plc , (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10 am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 2:05 pm ET.

Key Points: 
  • ICON plc , (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10 am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 2:05 pm ET.

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors

Retrieved on: 
Tuesday, February 27, 2024
CFO, ICON, ICON PLC, Biotechnology, Jazz Pharmaceuticals, Bank, Female, Growth, Greencore, Audit committee, Organization, Patient, McKinsey & Company, Chair, ASOS, KPMG, UDG Healthcare, Nightclub

DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors. Mr. Kennedy, Chair and Governor of the Bank of Ireland, has been appointed to the Jazz Board and will serve on the Audit Committee effective March 1, 2024. Peter Gray has decided not to seek re-election to the Jazz Board at the next Annual General Meeting, expected in July 2024.

Key Points: 
  • DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors.
  • Mr. Kennedy, Chair and Governor of the Bank of Ireland, has been appointed to the Jazz Board and will serve on the Audit Committee effective March 1, 2024.
  • "We are thrilled to welcome Patrick to the Board," said Bruce Cozadd, chairman and CEO, Jazz Pharmaceuticals.
  • Mr. Kennedy brings over 30 years of experience to the Jazz Board with a successful track record across a range of global businesses.